Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford.
Postgraduate School of Public Health, Health Education West Midlands, Birmingham.
Br J Gen Pract. 2018 Dec;68(677):e844-e851. doi: 10.3399/bjgp18X699809. Epub 2018 Nov 5.
Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation (AF), but are underused. AURAS-AF (AUtomated Risk Assessment for Stroke in AF) is a software tool designed to identify eligible patients and promote discussions within consultations about initiating anticoagulants.
To investigate the implementation of the software in UK general practice.
Process evaluation involving 23 practices randomly allocated to use AURAS-AF during a cluster randomised trial.
An initial invitation to discuss anticoagulation was followed by screen reminders appearing during consultations until a decision had been made. The reminders required responses, giving reasons for cases where an anticoagulant was not initiated. Qualitative interviews with clinicians and patients explored acceptability and usability.
In a sample of 476 patients eligible for the invitation letter, only 159 (33.4%) were considered suitable for invitation by their GPs. Reasons given were frequently based on frailty, and risk of falls or haemorrhage. Of those invited, 35 (22%) started an anticoagulant (7.4% of those originally identified). A total of 1695 main-screen reminders occurred in 940 patients. In 883 instances, the decision was taken not to initiate and a range of reasons offered. Interviews with 15 patients and seven clinicians indicated that the intervention was acceptable, though the issue of disruptive screen reminders was raised.
Automated risk assessment for stroke in atrial fibrillation and prompting during consultations are feasible and generally acceptable, but did not overcome concerns about frailty and risk of haemorrhage as barriers to anticoagulant uptake.
口服抗凝剂可降低房颤(AF)患者中风的风险,但使用不足。AURAS-AF(AF 中风自动风险评估)是一种软件工具,旨在识别合格患者,并在咨询中促进关于启动抗凝剂的讨论。
调查该软件在英国普通实践中的实施情况。
涉及 23 个实践的过程评估,这些实践在一项集群随机试验中被随机分配使用 AURAS-AF。
最初的抗凝讨论邀请之后,在咨询期间会出现屏幕提醒,直到做出决定。提醒需要回复,给出未启动抗凝剂的原因。对临床医生和患者进行定性访谈,探讨可接受性和可用性。
在符合邀请信条件的 476 名患者样本中,只有 159 名(33.4%)被他们的全科医生认为适合邀请。给出的理由通常基于脆弱性以及跌倒或出血的风险。在被邀请的人中,有 35 人(22%)开始使用抗凝剂(最初确定的 7.4%)。在 940 名患者中发生了 1695 次主要屏幕提醒。在 883 例情况下,决定不启动并提供了一系列理由。对 15 名患者和 7 名临床医生进行的访谈表明,该干预措施是可以接受的,尽管存在屏幕提醒干扰的问题。
心房颤动中风的自动风险评估和咨询期间的提示是可行且普遍可接受的,但并未克服对脆弱性和出血风险的担忧,这些因素是抗凝药物使用率低的障碍。